Updated:
Receptor Partners
Receptor Partners invests in the clinical pipeline of psychedelic medicine, with a portfolio of eight companies including Beckley Psytech, Psilera, and Cybin.
Receptor Partners
Receptor Partners is a private equity firm based in New York, US. It focuses on a Venture Capital investment approach.
General information
Firm type
Private Equity
Year founded
2017
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Sector focus
Frequently asked questions
What is Receptor Partners' investment thesis?
The firm targets the emerging regulatory pathway for psychedelic-derived therapeutics. It invests in companies developing compounds for mental health conditions, including depression, anxiety, and substance-use disorders. The portfolio spans discovery-stage platform companies and clinical-stage drug developers.
Which companies are in Receptor Partners' disclosed portfolio?
The firm's website lists eight positions: Beckley Psytech, Psilera, MindState Design, BrightMinds, Tactogen, Delix, Freedom Biosciences, and Cybin. These companies range from private preclinical-stage ventures to publicly traded clinical-stage biotechs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: